A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease (306A/306B)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01176240|
Recruitment Status : Completed
First Posted : August 5, 2010
Results First Posted : May 20, 2014
Last Update Posted : May 20, 2014
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
Post-randomization, up to 2 weeks dose titration followed by 8 wks at optimal dose.
The first 51 patients enrolled in the study were analyzed as a separate group in an interim analysis (Study 306A).
The final 171 patients remained blinded until the end of the study and analyzed as a separate study (Study 306B).